The scientific activity developed in the field of medical microbiology being transversal to antimicrobial resistance, epidemiology, and laboratory diagnosis of infectious diseases and aims to study the bacterial mechanisms underlying the emergence and evolution of drug resistance with epidemiological and clinical relevance aiming to use this information to develop medicines and technologies to combat bacterial infections.
Primary research relies on the study drug resistance in active and latent tuberculosis, understanding drug resistance mechanisms, exploring new anti-TB drugs and targets, and new mechanisms for killing M. tuberculosis. In addition, its research efforts are also focused on ways of combatting resistance mechanisms to existing drugs.
Research on the study of the evolution of M. tuberculosis multidrug resistant strains and genomic epidemiology/comparative genomics of clinical isolates circulating in Portugal and Portuguese-speaking countries such as Brazil, Angola, Guinea-Bissau and Mozambique. Study of resistance mechanisms of nontuberculous mycobacteria, especially, on macrolide resistance in Mycobacterium avium complex and Mycobacterium abscessus. Development of nanodiagnostics for tuberculosis.
Also interested in the study on antimicrobial resistance mechanisms of the Gram-negative bacterial species Acinetobacter baumannii and Escherichia coli, mainly B-lactams, carbapenems and colistin resistance, efflux pumps and discovery of new drugs/efflux inhibitors to tackle drug resistance and dissemination in these important microorganisms.
- Diana Machado, Tatiane Coelho, João Perdigão, Catarina Pereira, Isabel Couto, Isabel Portugal, Raquel Maschmann, Daniela Ramos, Andrea von Groll, Maria Rossetti, Pedro A. Silva, Miguel Viveiros. 2017. Interplay between mutations and efflux in drug resistant Mycobacterium tuberculosis clinical isolates. Front Microbiol. 8, 711.
- Diana Machado, David Pires, João Perdigão, Isabel Couto, Isabel Portugal, Marta Martins, Leonard Amaral, Elsa Anes, Miguel Viveiros. 2016. Ion channel blockers as antimicrobial agents, efflux inhibitors, and enhancers of macrophage killing activity against drug resistant Mycobacterium tuberculosis. PloS One. 11, e0149326.
- Emmanuelle Cambau, Miguel Viveiros, Diana Machado, Laurent Raskine, Claudia Ritter, Enrico Tortoli, Maryse Fauville-Dufaux, Sven Hoffner, Elvira Richter, Maria Perez del Molino, Daniella Cirillo, Dick van Soolingen, Erik C. Boettger. 2015. Revisiting susceptibility testing in multidrug resistant tuberculosis by a standardized quantitative phenotypic assessment in a European multicenter study. J Antimicrob Chemother. 70, 686-696.
- Diana Machado, João Perdigão, Jorge Ramos, Isabel Couto, Isabel Portugal, Claudia Ritter, Erik C. Boettger, Miguel Viveiros. 2013. High-level resistance to isoniazid and ethionamide in multidrug resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations. J Antimicrob Chemother. 68, 1728-1732.
- Diana Machado, Isabel Couto, João Perdigão, Liliana Rodrigues, Isabel Portugal, Pedro V. Baptista, Bruno Veigas, Leonard Amaral, Miguel Viveiros. 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One. 7, e34538.